Загрузка страницы

Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon

Topic: Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection
Speaker: Daniel Verdon
Presented at: International Workshop on HBV Cure 2018

Learn more about International Workshop on HBV Cure 2021 that will take place virtually on 26 September 2021 via hhttps://bit.ly/2SahmPj

The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment, and ultimately curing and eradicating HBV infection.

Since 2014, the International Workshop on HBV Cure has been a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people are chronically infected with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting is highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research.

For the Enduring Materials of the 2018 edition visit https://bit.ly/33Vejxl

For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/

Видео Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon канала Academic Medical Education
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
16 февраля 2021 г. 18:17:22
00:22:05
Другие видео канала
Preview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCPreview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDClinical Considerations of Aging People Living with HIV - Marta BoffitoClinical Considerations of Aging People Living with HIV - Marta BoffitoThe ABC of viral hepatitis | Mark Thursz, MRCPThe ABC of viral hepatitis | Mark Thursz, MRCPUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDСтигма и дискриминация в контексте группы людей, употребляющих инъекционные наркотики - Петр МейлахсСтигма и дискриминация в контексте группы людей, употребляющих инъекционные наркотики - Петр МейлахсSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchCase-Based Discussion of Oral Antivirals for COVID-19: Part 1  - Catia Marzolini, PharmD, PhDCase-Based Discussion of Oral Antivirals for COVID-19: Part 1 - Catia Marzolini, PharmD, PhDResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDInvitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Differentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDDifferentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDAcute hepatitis A to E, diagnosis and management | Thomas Berg, MDAcute hepatitis A to E, diagnosis and management | Thomas Berg, MDDoes resistance still matter? | Daniel Kuritzkes, MDDoes resistance still matter? | Daniel Kuritzkes, MD
Яндекс.Метрика